LadRx Corporation reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 4.2 million compared to USD 13.18 million a year ago. Basic loss per share from continuing operations was USD 11 compared to USD 35 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.3 USD | +2.68% | -2.13% | +76.92% |
Jun. 04 | LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License | CI |
May. 15 | LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
+76.92% | 1.14M | |
+17.09% | 44.63B | |
+42.10% | 40.46B | |
-9.70% | 38.07B | |
+33.28% | 32.27B | |
-8.98% | 27.3B | |
+13.37% | 26.53B | |
+44.11% | 14.06B | |
+32.33% | 12.54B | |
-7.26% | 11.28B |
- Stock Market
- Equities
- LADX Stock
- News LadRx Corporation
- LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2022